What Renhe Capital does

Renhe Capital (深圳人合资本管理有限公司, legally Shenzhen Renhe Capital Management Co., Ltd.) is a China-focused private equity and asset management firm founded in 2012 and registered in Shenzhen Qianhai, with operating headquarters at Investment Plaza, 27 Financial Street, Xicheng District, Beijing. The firm was among the first 100 private equity fund managers registered with the Asset Management Association of China (AMAC) in March 2014 and operates as a private securities investment fund manager under Chinese regulation. Its core business is growth-stage and mature-stage equity investment concentrated in two verticals: healthcare and medical technology (medical devices, biotech, pharmaceuticals, medical CRO) and advanced manufacturing (laser technology, new energy, hydrogen energy, environmental technology).

The firm manages 21 distinct private equity funds across vintages from 2012 (Phase 1 — Huayuanc Xingsheng) through 2023 (Phase 21 — Renhe Qinghe), with cumulative investment scale exceeding 20 billion RMB. Revenue is generated through two streams: recurring management fees on assets under management across the fund series, and performance-based carried interest from successful portfolio exits. Distribution is conducted via direct fundraising to institutional LPs (family offices, qualified domestic investors) through closed-end fund structures. The firm's go-to-market relies on professional network referrals, securities firm partnerships, and industry conference participation rather than mass marketing.

Renhe Capital's value proposition rests on deep sector specialization and a proven exit track record: portfolio companies including Xinchanye Biological (300832.SZ, 5.5x+ return), Medi-X Bio (688202.SH, 23x+ return), Mingde Bio (002932.SZ), Lianwin Laser (688518.SH), Innolase (301021.SZ), and Kaiyin Technology (688687.SH) have all achieved IPO exits. The firm also established a 2014 joint venture with Nomura Asset Management — Shenzhen Oriental Renhe Equity Investment Fund Management — creating a China-Japan cross-border PE platform. Recent activity includes a 100 million RMB+ lead investment in Gene Qiming Biotechnology (iNKT cell therapy) in January 2026 and continued expansion into hydrogen energy and new-energy themes through dedicated fund vintages.

Name

Renhe Capital

Legal name

深圳人合资本管理有限公司

Website

https://renheamc.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

11–50 employees

Short description

Renhe Capital is a China-focused private equity and asset management firm managing 21 PE funds (cumulative 20+ billion RMB) that invests growth and mature-stage capital in healthcare, medical technology, advanced manufacturing, and new energy sectors, serving institutional LPs and achieving multiple IPO exits.

Ownership category

akta.pro rank

Product category

Private Equity Fund Management

NAICS

Other Investment Pools and Funds (5259), Portfolio Management and Investment Advice (523940)

SIC

Security Brokers, Dealers & Flotation Companies (6211), Investment Advice (6282)

akta.pro primary industry

Small-Cap Equity (Active) (FSAAAIAC)

Keywords

• Private equity investment
• Asset management
• Fund management
• Growth capital
• IPO preparation

Headquarters

HQ city

Shenzhen

HQ country

China

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Fund Management Fees: Management fees charged on assets under management across 21 private equity funds
2. Performance Fees (Carried Interest): Performance-based carried interest from successful portfolio company exits and IPOs

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Renhe Capital is a professional asset management firm that manages 21 closed-end private equity funds focused on growth-stage and mature-stage equity investments in China's healthcare and advanced manufacturing sectors. It raises capital from institutional investors and qualified domestic LPs, then deploys capital via direct equity investments and private placements in listed companies, providing post-investment value-add services such as IPO preparation, M&A advisory, and governance improvement to drive exits.

Product overview

Renhe Capital operates as a professional asset management company specializing in private equity investment and private placement for listed companies. The company manages a portfolio of 21 named investment funds covering healthcare and advanced manufacturing sectors. Core business lines include equity investment in growth and mature-stage companies, fund management services, and value-added investment support for portfolio companies. Renhe Capital does not offer technology products or software services—its offerings are financial products focused on capital deployment and investment management rather than technology solutions.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• Multiple portfolio companies have achieved successful IPOs and significant returns
• +2 more outcomes

Named customers9 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• Nomura Asset Management (野村资产管理)coreStrategic or Co-development Partner · 1 January 2014In 2014, Renhe Capital formed a joint venture with Nomura Asset Management, the largest securities firm in Japan, to establish Shenzhen Oriental Renhe Private Equity Fund Management Co., Ltd. This joint venture combines Nomura's global resources with Renhe Capital's local expertise in China, creating a platform for international investors to access China's equity investment market.

Scale indicators8 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• CDH Investments: CDH Investments is one of China's largest alternative asset managers, with significant PE exposure across healthcare, industrials, and consumer. A broader incumbent operating at much larger AUM, but historically the benchmark for Chinese growth-stage PE and a relevant comparator for LP decision-making.
• Hillhouse Capital: Hillhouse Capital is a leading global investment manager of Asian equities with a deep healthcare and consumer franchise. A broader incumbent peer operating at much larger AUM, but overlapping heavily in China healthcare investing, late-stage growth equity, and LP fundraising.
• Citic Capital Holdings: Citic Capital is a Hong Kong/China-headquartered alternative investment manager with significant PE operations in growth and buyout deals across healthcare and industrials. A broader incumbent peer with overlapping sector focus and a similar cross-border (China/HK) footprint.
• CICC Capital: CICC Capital is the private investment arm of China International Capital Corporation, a top-tier Chinese investment bank with PE operations spanning growth and mature-stage healthcare, TMT, and industrials. A broader incumbent with similar China growth-equity and IPO-focused thesis.

Direct peers

• Loyal Valley Capital: Loyal Valley Capital (正心谷资本) is a Chinese PE firm focused on growth-stage healthcare, consumer, and technology companies. Comparable in sector tilt (healthcare-heavy), growth-stage mandate, and similar mid-to-large fund vintages.
• Legend Capital: Legend Capital is a leading China-focused PE/VC firm (originated from Legend Group) investing in growth-stage healthcare, TMT, and advanced manufacturing. Directly comparable to Renhe Capital given similar vintage of operation, sector focus on healthcare and industrial technology, and PE growth-stage mandate.
• Fortune Capital: Fortune Capital (达晨财智) is a top-tier Chinese PE firm headquartered in Shenzhen, investing in growth-stage companies across advanced manufacturing, healthcare, and TMT. Comparable in scale, sector focus, and Shenzhen/regional roots, and a direct peer for Chinese growth-stage PE allocations.
• Shenzhen Capital Group: Shenzhen Capital Group (深创投) is one of China's largest state-affiliated VC/PE platforms, headquartered in Shenzhen, with broad sector coverage including healthcare and advanced manufacturing. Comparable given shared Shenzhen domicile, multi-fund structure, and growth-stage investment focus.
• Eastern Bell Capital: Eastern Bell Capital (钟鼎资本) is a China-focused growth PE with supply chain, logistics, and advanced industrials exposure. Comparable given similar fund series structure, growth-stage Chinese industrials focus, and institutional LP base.

Emerging players

• Volcanics Venture: Volcanics Venture (火山石资本) is a China-focused healthcare investor with overlap in biotech and medical devices. Comparable given healthcare-only sector focus and growth-stage China mandate, though smaller and more venture-leaning.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments39 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Renhe Capital